BIIB - Many Alzheimer's drug developers close significantly higher thanks to Biogen Eisai data

Biogen ( NASDAQ: BIIB ) and Eisai ( OTCPK:ESALY ) weren't the only drug companies developing Alzheimer's treatments that finished Wednesday significantly higher.

The duo closed up, respectively, 40% and ~58% higher following Tuesday's after the market close release of phase 3 data for Alzheimer's candidate lecanemab .

That helped boost the fortune of other Alzheimer's therapy developers. The best performer of the day was Acumen Pharmaceuticals, which ended the day up ~104% . The company has the anti-amyloid-beta oligomer monoclonal antibody ACU193, currently in phase 1.

The second best Alzheimer's-related developer of the day was Prothena Corp. ( PRTA ), closing up nearly 88% . It has two clinical Alzheimer's candidates, PRX005 and PRX012, both in phase 1. They are antibodies. PRX005 targets tau protein while PRX012 targets amyloid protein.

AC Immune ( ACIU ) added ~24% . In phase 2, in collaboration with Roche's ( OTCQX:RHHBY ) Genentech unit, it is developing the anti-tau antibody semorinemab. And in phase 1, in collaboration with Johnson & Johnson's ( JNJ ) Janssen unit, it has the anti-tau vaccine ACI-35.030.

Other Alzheimer's-related stocks that closed higher today include Annovis Bio ( ANVS ), Anavex Life Sciences ( AVXL ), and Cognition Therapeutics ( CGTX ).

Roche ( OTCQX:RHHBF ), which is developing gantenerumab, and Eli Lilly ( LLY ), which is developing donanemab, also closed higher.

The one Alzheimer's stock that finished down was Cassava Sciences ( SAVA ), which has the oral medication simufilam in its pipeline. It closed off 5% .

For further details see: